December 29, 2004 -- Stocks consolidated their recent gains on Wednesday, after closing at record levels the day before. The Centient Biotech 200 was lower by 1.48 points, a .03% decline, closing at 3611.23. The NYSE Composite dropped .05% while Nasdaq lost just .01%. Genzyme received an important FDA approval, Repligen’s stock climbed mysteriously, and ImmunoGen made a follow-up move.
